TY - JOUR KW - Erythema nodosum leprosum KW - erythema nodosum leprosum KW - lepra reaction KW - thalidomide AU - Bhat RM AU - Vaidya T AB -

Erythema nodosum leprosum (ENL) is a manifestation of type II lepra reaction, seen in lepromatous or borderline lepromatous leprosy. Although it is a common reaction encountered in clinical practice, there are an increasingly large number of newer updates in the pathophysiology and management of this condition. The treatment options have expanded far beyond just thalidomide and steroids and now extends to TNF-α inhibitors, thalidomide analogs, tenidap, cyclosporine A, plasma exchange, and even IVIG amongst others. These updates and the current knowledge of ENL are summarized in this review.

BT - Indian dermatology online journal C1 - https://www.ncbi.nlm.nih.gov/pubmed/32832433 DA - 01/2020 DO - 10.4103/idoj.IDOJ_561_19 IS - 4 J2 - Indian Dermatol Online J LA - eng N2 -

Erythema nodosum leprosum (ENL) is a manifestation of type II lepra reaction, seen in lepromatous or borderline lepromatous leprosy. Although it is a common reaction encountered in clinical practice, there are an increasingly large number of newer updates in the pathophysiology and management of this condition. The treatment options have expanded far beyond just thalidomide and steroids and now extends to TNF-α inhibitors, thalidomide analogs, tenidap, cyclosporine A, plasma exchange, and even IVIG amongst others. These updates and the current knowledge of ENL are summarized in this review.

PY - 2020 SP - 482 EP - 492 T2 - Indian dermatology online journal TI - What is New in the Pathogenesis and Management of Erythema Nodosum Leprosum. UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413435/ VL - 11 SN - 2229-5178 ER -